Histone deacetylases (HDACs): Characterization of the classical HDAC family

Biochemical Journal

Volumn 370, Issue 3, 2003, Pages 737-749

  De Ruijter, Annemieke J M ^a   Van Gennip, Albert H ^a   Caron, Huib N ^a   Kemp, Stephan ^a   Van Kuilenburg, André B P ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Characterization; Co repressor; Gene expression; Histone deacetylase; Inhibitor; Tissue distribution

Indexed keywords

CHEMICAL REACTIONS; CHROMATES; ENZYMES; GENES; ORGANIC SOLVENTS; TISSUE;

EUKARYOTES; HISTONE DEACETYLASES (HDAC);

BIOCHEMISTRY;

4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BENZAMIDE; BUTYRIC ACID; CARBOXYCINNAMIC ACID BISHYDROXAMIDE; CELL NUCLEUS RECEPTOR; EPOXIDE; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; ISOENZYME; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PROTEIN; PYROXAMIDE; SHORT CHAIN FATTY ACID; SILENCING MEDIATOR FOR RETINOIC ACID AND THYROID HORMONE RECEPTOR; SUBEROYL ANILIDE BISHYDROXAMIDE; TETRAPEPTIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLATION; ANALYTIC METHOD; APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE; CHROMOSOME; CLINICAL TRIAL; CYTOTOXICITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GROWTH DISORDER; HUMAN; IN VITRO STUDY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHYLOGENY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SACCHAROMYCES CEREVISIAE; SERIAL ANALYSIS OF GENE EXPRESSION; TISSUE DISTRIBUTION; TISSUE TYPES; TRANSCRIPTION REGULATION;

ACETYLATION; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HISTONES; HUMANS; ISOENZYMES; MODELS, GENETIC; MOLECULAR STRUCTURE; NEOPLASMS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC;

EUKARYOTA; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0037444803     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20021321     Document Type: Review

References (125)

1. Wade, P. A. (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 10, 693-698
2. Ito, K., Barnes, P. J. and Adcock, I. M. (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12 Mol. Cell. Biol, 20, 6891-6903
3. Strahl, B. D. and Allis, C. D. (2000) The language of covalent histone modifications. Nature (London) 403, 41-45
4. Bjerling, P., Silverstein, R. A., Thon, G., Caudy, A., Grewal, S. and Ekwall, K. (2002) Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol. Cell. Biol. 22, 2170-2181
5. Forsberg, E. C. and Bresnick, E. H. (2001) Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays 23, 820-830
6. Cress, W. D. and Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184, 1-16
7. Timmermann, S., Lehrmann, H., Polesskaya, A. and Harel-Bellan, A. (2001) Histone acetylation and disease. Cell. Mol. Life Sci. 58, 728-736
8. He, L. Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, Jr, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M. and Pandolfi, P. P. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321-1330
9. Zhou, D. C., Kim, S. H., Ding, W., Schultz, C., Warrell, R. P. J. and Gallagher, R. E. (2002) Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99, 1356-1363
10. Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A. and Richon, V. M. (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61, 8492-8497
11. Minucci, S., Nervi, C., Lo, C. F. and Pelicci, P. G. (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110-3115
12. Ferrara, F. F., Fazi, F., Bianchini, A., Padula, F., Gelmetti, V., Minucci, S., Mancini, M., Pelicci, P. G., Lo Coco, F. and Nervi, C. (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7
13. Kitamura, K., Hoshi, S., Koike, M., Kiyoi, H., Saito, H. and Naoe, T. (2000) Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 108, 696-702
14. David, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A. and Dejean, A. (1998) Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16, 2549-2556
15. Jones, P. A. and Baylin, S. B. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428
16. Baylin, S. B. and Herman, J. G. (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16, 168-174
17. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. and Baylin, S. B. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103-107
18. Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G. and Davidson, N. E. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61, 7025-7029
19. Johnstone, R. W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery 1, 287-299
20. Yah, L., Yang, X. and Davidson, N. E. (2001) Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J. Mammary Gland Biol. Neoplasia 6, 183-192
21. Zhu, W. G., Lakshmanan, R. R., Beal, M. D. and Otterson, G. A. (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61, 1327-1333
22. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X. F. and Yao, T. P. (2002) HDAC6 is a microtubule-associated deacetylase. Nature (London) 417, 455-458
23. Juan, L. J., Shia, W. J., Chen, M. H., Yang, W. M., Seto, E., Lin, Y. S. and Wu, C. W. (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275, 20436-20443
24. Suenaga, M., Soda, H., Oka, M., Yamaguchi, A., Nakatomi, K., Shiozawa, K., Kawabata, S., Kasai, T., Yamada, Y., Kamihira, S. et al. (2002) Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int. J. Cancer 97, 621-625
25. Pelidis, M. A., Carducci, M. A. and Simons, J. W. (1998) Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int. J. Oncol. 12, 889-893
26. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G. and Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978
27. Della Ragione, F., Criniti, V., Della Pietra, V., Borriello, A., Oliva, A, Indaco, S., Yamamoto, T. and Zappia, V. (2001) Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett. 499, 199-204
28. Remiszewski, S. W., Sambucetti, L. C., Atadja, P., Bair, K. W., Cornell, W. D., Green, M. A., Howell, K. L., Jung, M., Kwon, P., Trogani, N. and Walker, H. (2002) Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 45, 753-757
29. Lavoie, R., Bouchain, G., Frechette, S., Woo, S. H., Khalil, E. A., Leit, S., Fournel, M., Yan, P. T., Trachy-Bourget, M., Beaulieu, C. et al. (2001) Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 11, 2847-2850
30. Kim, M. S., Son, M. W., Kim, W. B., In, P. Y. and Moon, A. (2000) Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157, 23-30
31. Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R., Piekarz, R. L., Tucker, E., Figg, W. D. et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728
32. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T. and Kelly, W. K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202
33. Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S. and Beppu, T. (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268, 22429-22435
34. Van Lint, C., Emiliani, S. and Verdin, E. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expression 5, 245-253
35. Mariadason, J. M., Corner, G. A. and Augenlicht, L. H. (2000) Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60, 4561-4572
36. Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W. and Verdin, E. (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45-57
37. Gao, L., Cueto, M. A., Asselbergs, F. and Atadia, P. (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277, 25748-25755
38. Buggy, J. J., Sideris, M. L., Mak, P., Lorimer, D. D., McIntosh, B. and Clark, J. M. (2000) Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem. J. 350, 199-205
39. Galasinski, S. C., Resing, K. A., Goodrich, J. A. and Ahn, N. G. (2002) Phosphatase inhibition leads to histone deacetylase 1/2 phosphorylation and disruption of co-repressor interactions. J. Biol. Chem. 277, 19618-19626
40. Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W. and Verdin, E. (2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem. 276, 35826-35835
41. Yang, W. M., Tsai, S. C., Wen, Y. D., Fejer, G. and Seto, E. (2002) Functional domains of histone deacetylase-3. J. Biol. Chem. 277, 9447-9454
42. Van den Wyngaert, I., de Vries, W., Kremer, A., Neefs, J., Verhasselt, P., Luyten, W. H. and Kass, S. U. (2000) Cloning and characterization of human histone deacetylase 8. FEBS Lett. 478, 77-83
43. Bertos, N. R., Wang, A. H. and Yang, X. J. (2001) Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243-252
44. Fischer, D. D., Cai, R., Bhatia, U., Asselbergs, F. A., Song, C., Terry, R., Trogani, N., Widmer, R., Atadja, P. and Cohen, D. (2002) Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. 277, 6656-6666
45. Kao, H. Y., Lee, C. H., Komarov, A., Han, C. C. and Evans, R. M. (2002) Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 277, 187-193
46. Zhou, X., Marks, P. A., Rifkind, R. A. and Richon, V. M. (2001) Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. U.S.A. 98, 10572-10577
47. Pflum, M. K., Tong, J. K., Lane, W. S. and Schreiber, S. L. (2001) Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation. J. Biol. Chem. 276, 47733-47741
48. Kao, H. Y., Verdel, A., Tsai, C. C., Simon, C., Juguilon, H. and Khochbin, S. (2001) Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 276, 47496-47507
49. Dressel, U., Bailey, P. J., Wang, S. C., Downes, M., Evans, R. M. and Muscat, G. E. (2001) A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J. Biol. Chem. 276, 17007-17013
50. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N. and Horinouchi, S. (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48 (Suppl. 1), S20-S26
51. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R. and Pavletich, N. P. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (London) 401, 188-193
52. Yoshida, M., Kijima, M., Akita, M. and Beppu, T. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179
53. Marmorstein, R. (2001) Structure of histone deacetylases: insights into substrate recognition and catalysis. Structure 9, 1127-1133
54. Kao, H. Y., Downes, M., Ordentlich, P. and Evans, R. M. (2000) Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 14, 55-66
55. Li, J., Lin, Q., Wang, W., Wade, P. and Wong, J. (2002) Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev. 16, 687-692
56. Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A. and Reinberg, D. (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924-1935
57. Brehm, A., Miska, E. A., McCance, D. J., Reid, J. L., Bannister, A. J. and Kouzarides, T. (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (London) 391, 597-601
58. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R. et al. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (London) 387, 43-48
59. Ashburner, B. P., Westerheide, S. D. and Baldwin, A. S. J. (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21, 7065-7077
60. Taplick, J., Kurtev, V., Kroboth, K., Posch, M., Lechner, T. and Seiser, C. (2001) Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J. Mol. Biol. 308, 27-38
61. Yao, Y. L., Yang, W. M. and Seto, E. (2001) Regulation of transcription factor YY1 by acetylation and deacetylation. Mol. Cell. Biol. 21, 5979-5991
62. Koipally, J., Renold, A., Kim, J. and Georgopoulos, K. (1999) Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J. 18, 3090-3100
63. Wu, X., Li, H., Park, E. J. and Chen, J. D. (2001) SMRTE inhibits MEF2C transcriptional activation by targeting HDAC4 and 5 to nuclear domains. J. Biol. Chem. 276, 24177-24185
64. Nair A. R., Boersma, L. J., Schlitz, L., Chaudry, A. and Muschel, R. J. (2001) Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett. 166, 55-64
65. Guenther, M. G., Barak, O. and Lazar, M. A. (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21, 6091-6101
66. Ozawa, Y., Towatari, M., Tsuzuki, S., Hayakawa, F., Maeda, T., Miyata, Y., Tanimoto, M. and Saito, H. (2001) Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood 98, 2116-2123
67. Zhou, X., Richon, V. M., Rifkind, R. A. and Marks, P. A. (2000) Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc. Natl. Acad. Sci. U.S.A. 97, 1056-1061
68. Nicolas, E., Alt-Si-Ali, S. and Trouche, D. (2001) The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. Nucleic Acids Res. 29, 3131-3136
69. Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G. F., Johanson, K., Sung, C. M., Liu, R. and Winkler, J. (2000) Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 275, 15254-15264
70. McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2001) Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 11, 497-504
71. Andreucci, J. J., Grant, D., Cox, D. M., Tomc, L. K., Prywes, R., Goldhamer, D. J., Rodrigues, N., Bedard, P. A. and McDermott, J. C. (2002) Composition and function of AP-1 transcription complexes during muscle cell differentiation. J. Biol. Chem. 277, 16426-16432
72. McKinsey, T. A., Zhang, C. L., Lu, J. and Olson, E. N. (2000) Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature (London) 408, 106-111
73. Miska, E. A., Langley, E., Wolf, D., Karlsson, C., Pines, J. and Kouzarides, T. (2001) Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res. 29, 3439-3447
74. Choi, S. J., Park, S. Y. and Han, T. H. (2001) 14-3-3tau associates with and activates the MEF2D transcription factor during musde cell differentiation. Nucleic Acids Res. 29, 2836-2842
75. Guardiola, A. R. and Yao, T. P. (2002) Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 277, 3350-3356
76. Tong, J. J., Liu, J., Bertos, N. R. and Yang, X. J. (2002) Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30, 1114-1123
77. Caron, H., van Schaik, B., van derMee, M., Baas, F., Riggins, G., van Sluis, P., Hermus, M. C., van Asperen, R., Boon, K., Voute, P. A. et al. (2001) The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science 291, 1289-1292
78. Dangond, F., Henriksson, M., Zardo, G., Caiafa, P., Ekstrom, T. J. and Gray, S. G. (2001) Differential expression of class I HDACs: roles of cell density and cell cycle. Int. J. Oncol 19, 773-777
79. Dangond, F. and Gullans, S. R. (1998) Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem. Biophys. Res. Commun. 247, 833-837
80. Gray, S. G. and Ekstrom, T. J. (2001) The human histone deacetylase family. Exp. Cell Res. 262, 75-83
81. Chang, K. T. and Min, K. T. (2002) Regulation of lifespan by histone deacetylase. Ageing Res. Rev. 1, 313-326
82. Robyr, D.; Suka, Y., Xenarios, I., Kurdistani, S. K., Wang, A., Suka, N. and Grunstein, M. (2002) Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell 109, 437-446
83. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M. and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 98, 87-92
84. Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M. and Horinouchi, S. (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18, 2461-2470
85. Kramer, O. H., Gottlicher, M. and Heinzel, T. (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12, 294-300
86. Marks, P. A., Richon, V. M., Breslow, R. and Rifkind, R. A. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13, 477-483
87. Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L., Zalupski, M., Radulovic, L., Valdivieso, M. and LoRusso, P. M. (2001) Chronic oral administration of Cl-994: a phase 1 study. Invest. New Drugs 19, 1-11
88. Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L., Figg, W. D., Zabelina, Y., Donehower, R. C. and Carducci, M. A. (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7, 2292-2300
89. Gore, S. D., Weng, L. J., Zhai, S., Figg, W. D., Donehower, R. C., Dover, G. J., Grever, M, Griffin, C. A., Grochow, L. B., Rowinsky, E. K. et al. (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8, 963-970
90. Warrell, Jr, R. P., He, L. Z., Richon, V., Calleja, E. and Pandolfi, P. P. (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90, 1621-1625
91. Grandori, C., Cowley, S. M., James, L. P. and Eisenman, R. N. (2000) The Myc/Max/Mad network and the transcriptional control of cell behaviour. Annu. Rev. Cell Dev. Biol. 16, 653-699
92. Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R. and Bates, S. E. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98, 2865-2868
93. Richon, V. M. and O'Brien, J. P. (2002) Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment: commentary. Clin. Cancer Res. 8, 662-664
94. WAF1/Cip1 transcription through Sp1 sites by histone deacetylase inhibitor apicidin: Involvement of protein kinase C. J. Biol. Chem. 276, 42084-42090
95. Zhang, C. L., McKinsey, T. A. and Olson, E. N. (2002) Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell. Biol. 22, 7302-7312
96. Su, G. H., Sohn, T. A., Ryu, B. and Kern, S. E. (2000) A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60, 3137-3142
97. Yu, X., Guo, Z. S., Marcu, M. G., Neckers, L., Nguyen, D. M., Chen, G. A and Schrump, D. S. (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94, 504-513
98. Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T. R., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon-Cardo, C. and Scher, H. I. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962-970
99. Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A. Richon, V. M. and La Quaglia, M. P. (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59, 4392-4399
100. Han, J. W., Ahn, S. H., Park, S. H., Wang, S. Y., Bae, G. U., Seo, D. W., Kwon, H. K., Hong, S., Lee, H. Y., Lee, Y. W. and Lee, H. W. (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60, 6068-6074
101. Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I. and Coombes, R. C. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7, 971-976
102. Nervi, C., Borello, U., Fazi, F., Buffa, V., Pelicci, P. G. and Cossu, G. (2001) Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res. 61, 1247-1249
103. Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M. and La Quaglia, M. P. (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61, 3591-3594
104. Siavoshian, S., Segain, J. P., Kornprobst, M., Bonnet, C., Cherbut, C., Galmiche, J. P. and Blottiere, H. M. (2000) Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 46, 507-514
105. Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L., Rifkind, R., Marks, P. A., Richon, V. M. and LaQuaglia, M. P. (2000) Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med. Pediatr. Oncol. 35, 577-581
106. Sun, H. and Taneja, R. (2000) Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 97, 4058-4063
107. Koyama, Y., Adachi, M., Sekiya, M., Takekawa, M. and Imai, K. (2000) Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 96, 1490-1495
108. Hou, M., Wang, X., Popov, N., Zhang, A., Zhao, X., Zhou, R., Zetterberg, A., Bjorkholm, M., Henriksson, M., Gruber, A. and Xu, D. (2002) The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp. Cell Res. 274, 25-34
109. Lavelle, D., Chen, Y. H., Hankewych, M. and DeSimone, J. (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am. J. Hematol. 68, 170-178
110. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T. and Nakanishi, O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 96, 4592-4597
111. Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J. and Schreiber, S. L. (1998) Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 95, 3356-3361
112. Marks, P. A., Richon, V. M. and Rifkind, R. A. (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216
113. Woo, S. H., Frechette, S., Khalil, E. A., Bouchain, G., Vaisburg, A., Bernstein, N., Moradei, O., Leit, S., Allan, M., Fournel, M. et al. (2002) Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem. 45, 2877-2885
114. Vaute, O., Nicolas, E., Vandel, L. and Trouche, D. (2002) Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res. 30, 475-481
115. Downes, M., Ordentlich, P., Kao, H. Y., Alvarez, J. G. and Evans, R. M. (2000) Identification of a nuclear domain with deacetylase activity. Proc. Natl. Acad. Sci. U.S.A. 97, 10330-10335
116. Yang, J., Kawai, Y., Hanson, R. W. and Arinze, I. J. (2001) Sodium butyrate induces transcription from the G alpha(I2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J. Biol. Chem. 276, 25742-25752
117. Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. and Carducci, M. A. (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 61, 1477-1485
118. Stahelin, H. and Trippmacher, A. (1974) Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Eur. J. Cancer 10, 801-808
119. Kitazono, M., Rao, V. K., Robey, R., Aikou, T., Bates, S, Fojo, T. and Goldsmith, M. E. (2002) Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood 99, 2248-2251
120. Kwon, H. J., Kim, M. S., Kim, M. J., Nakajima, H. and Kim, K. W. (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 97, 290-296
121. Seelig, M. H. and Berger, M. R. (1996) Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur. J. Cancer 32A, 1968-1976
122. Burgess, A. J., Pavey, S., Warrener, R., Hunter, L. J., Piva, T. J., Musgrove, E. A., Saunders, N., Parsons, P. G. and Gabrielli, B. G. (2001) Up-regulation of p21(WAF1/ClP1) by histone deacetylase inhibitors reduces their cytotoxicity Mol. Pharmacol. 60, 828-837
123. Richon, V. M., Sandhoff, T. W., Rifkind, R. A. and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97, 10014-10019
124. Huang, H., Reed, C. P., Zhang, J. S., Shridhar, V., Wang, L. and Smith, D. I. (1999) Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 59, 2981-2988
125. Khochbin, S., Verdel, A., Lemercier, C. and Seigneurin-Berny, D. (2001) Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11, 162-166